



PROGRAMME

WORKSHOPS Sunday 2nd June - Imperial College

09:00 – 10:00				Registration & Coffee			
				Queen's Tower Rooms, Sherfield Building, Imperial College London			
10:00 – 12:30		Workshop 1 Basic Science – Animal Models Luc Willems, Genoveffa Franchini & Pat Green		Workshop 2 Clinical: Prognostic Markers Aileen Rowan, Jorge Casseb & Kaoru Uchimani		Workshop 3 Elimination of mother-to-child transmission Carolina Rosadas, Andrea Thoma-Kress & Hermione Lyall	
12:30 – 13:45				Lunch			
				Demonstration of HAL (hybrid assisted limb) system by Cyberdyne			
13:45 – 16:15		Workshop 4 Molecular Virology Anne van den Broeke & Damian Purcell		Workshop 5 International Collaboration Raymond Cesaire & Lucy Cook		Workshop 6 Public Health Fabiola Martin & Leandro Sereno	
16:15 – 19:00				Welcome Reception			
				Queen's Tower Rooms			



HTLV

CONFERENCE

2nd-5th June 2024

Imperial College London & Royal College of Physicians

DAY 1: Monday 3rd June 2024 – Royal College of Physicians

All plenary sessions will be held in the Wolfson Theatre

09:00- 10:30	<p style="text-align: center;">Opening Plenary</p> <p style="text-align: center;">Welcome Fabiola Martin, President IRVA /Graham Taylor Conference Chair Department of Infectious Disease, Imperial College London</p> <p style="text-align: center;">Patients' perspectives</p> <p style="text-align: center;">WHO representative</p> <p style="text-align: center;">Guest of Honour Isabel Oliver, UKHSA Chief Scientific Officer</p> <p style="text-align: center;">Keynote lecture - Brazil's strategy to eliminate HTLV-1 mother-to-child transmission Angelica Espinosa Miranda, Ministry of Health, Brazil</p>
10:30-11:00	Tea & Coffee – Osler Long room
11:00– 12:30	<p style="text-align: center;">Symposium 1 The Global picture Chairs: Antoine Gessain, Institute Pasteur, France & Edward Murphy, UCSF, USA</p> <p style="text-align: center;">O01 Current status and future perspectives of HTLV infection in Uruguay Florencia Rammauro, Universidad de la República & Institut Pasteur Montevideo, Uruguay</p> <p style="text-align: center;">O02 Completing the picture: HTLV testing and diagnoses in England, 2005 to 2021 India Clancy, UK Health Security Agency, United Kingdom</p> <p style="text-align: center;">O03 The origin and diversity of HTLV-1 in South America: a complete genome and Bayesian approach Daniel Enriquez-Vera, Division of HTLV-1/ATL Carcinogenesis and Therapeutics, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Japan</p> <p style="text-align: center;">O04 Evidence of HTLV-1 infection through serological survey in remote areas of the northern region of Sabah state, Borneo Island, Malaysia Hidekatsu Iha, Oita University Faculty of Medicine, Japan</p> <p style="text-align: center;">O06 ATL incidence and HTLV-1 serology in the French Antilles over the past decade Raymond Césaire, Faculty of Medicine, University of Antilles, French West Indies</p> <p style="text-align: center;">O07 Antigenicity of HTLV-1 subtype C Env in natural infection Samantha Grimley, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia</p>
12:30-13:45	Lunch - Osler Long room
13:45 – 15:30	<p style="text-align: center;">Symposium 2 Advances in the treatment of ATL Chairs: Ali Bazarbachi, American University of Beirut, Beirut and Shigeo Fuji, Osaka International Cancer Institute, Japan</p>



HTLV

CONFERENCE

2nd-5th June 2024

Imperial College London & Royal College of Physicians

	<p>O08 Prevalence and Outcomes of HTLV-1-associated Adult T-cell Leukemia/Lymphoma in Latin America: A Retrospective Cohort Analysis Bryan Valcarcel, NIH/NCI, USA</p> <p>O09 25-year evolution of allogeneic hematopoietic stem cell transplantation for ATL at Imamura General Hospital Nobuaki Nakano, Seifukai Clinic/Imamura General Hospital, Japan</p> <p>O10 Allogeneic hematopoietic stem cell transplantation is effective for patients with adult t cell leukemia/ lymphoma and can eradicate HTLV-1 infection: a retrospective monocentric study Ambroise Marçais, APHP, Necker Hospital, France</p> <p>O11 A novel surface antigen and immunotherapeutic strategy for Adult T-cell Leukemia-Lymphoma Kako Suzuki, The University of Tokyo, Japan</p> <p>O12 A randomized, open-label, multicenter, 2-dose parallel-group, phase II study of bexarotene in patients with ATL (B-1801 study) Kentaro Yonekura, Department of Dermatology, Imamura General Hospital, Japan</p> <p>O13 Final Safety and Early Efficacy Results of AZT plus Interferon-alfa with Belinostat (AI-BEL) for ATL Juan Carlos Ramos, University of Miami, USA</p> <p>O14 Clinical response in the Belinostat trial with zidovudine plus interferon for ATLL is associated with the expansion of a unique subset of cytolytic T cells B.Hilda Ye, Albert Einstein College of Medicine, USA</p> <p>O15 Frontline Brentuximab-Vedontin combined with CHP-like chemotherapy for CD30 express... Louise Naveau, Necker Hospital, France</p>
15:30 – 16:00	Tea & Coffee - Osler Long room
16:00 – 17:00	<p>Symposium 3 Learning from other infections Chairpersons: Eduardo Gotuzzo, Universidad Peruana Cayetano Heredia and Divya Dhasmana, St Marys Hospital, UK</p> <p>O16 Use of ART is associated with reduced HTLV-1 proviral load in HIV-HTLV-1 coinfecting patients Carlos Brites, School of Medicine, Federal University of Bahia, Brazil</p> <p>O17 Dolutegravir and tenofovir alafenamide block HTLV-1 transmission in vitro – it's time to eradicate HTLV-1 Mphatso D.Kalemera, Imperial College London, United Kingdom</p> <p>O18 HTLV-1 infection and cervicovaginal susceptibility to high-risk HPV: findings from HTLV-1-infected women in Salvador, Brazil Fernanda Grassi, Researcher, FIOCRUZ, Brazil</p> <p>O20 Infants of hepatitis B surface antigen positive women in the UK are at risk of HTLV-1 acquisition Daniel Bradshaw, UK Health Security Agency / National Centre for Human Retrovirology, United Kingdom</p>




HTLV

CONFERENCE

2nd-5th June 2024

Imperial College London & Royal College of Physicians



17:00 – 19:00	Poster Session -1 ODD-numbered posters to be presented (all posters can be displayed) Osler Long Room
19:00	Free evening

DAY 2: Tuesday 4th June 2024 – Royal College of Physicians

09:00 – 10:50	<p style="text-align: center;">Symposium 4 Understanding HTLV infection at the molecular level Chairs: & Amanda Panfil, The Ohio State University, USA and Lee Ratner, Washington University, USA</p> <p style="text-align: center;">O21 Identification of the cellular factor UHRF1 as a new epigenetic repressor of HTLV-1 transcription Estelle Plant, Université Libre de Bruxelles, Belgium</p> <p style="text-align: center;">O22 SRPK1 interacts with the HTLV-1 hbz mRNA and influences cellular proliferation Rocio Zaldivar, The Ohio State University, USA</p> <p style="text-align: center;">O23 Targeting ATL with an anti-transferin receptor Olivier Hermine, Necker Hospital and Imagine Institute, APHP, University of Paris, INSERM U1163, Paris, France</p> <p style="text-align: center;">O24 Long distance control of immunity in HAM/TSP via exosomes Pooja Jain, Drexel University College of Medicine, USA</p> <p style="text-align: center;">O25 Inhibition of KDR/VEGFR2 promotes HTLV-1 Tax degradation and the selective depletion of Tax+ HTLV-1-infected T cells Edward Harhaj, Penn State College of Medicine, USA</p> <p style="text-align: center;">O26 Tissue-specific mechanism and tumor heterogeneity in lymphoma-type ATL Mitsuyoshi Takatori, Kumamoto University, Japan</p> <p style="text-align: center;">O27 Characterizing the role of N-6-methyladenosine in the oncogenic retrovirus HTLV-1 Emily King, The Ohio State University, USA</p> <p style="text-align: center;">O28 Inhibition of the signal peptidase complex blocks cleavage of HTLV-1 ORF1-encoded p12 into p8 Florian Simon, Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Germany</p> <p style="text-align: center;">O29 HBZ-related dysregulation in circular RNA biogenesis during ATL development Julien Ladet, LBMC – ENS de Lyon, France</p>
10:50 – 11:10	Tea & Coffee - Osler Long room



HTLV

CONFERENCE

2nd-5th June 2024

Imperial College London & Royal College of Physicians

11:10 – 12:10	<p style="text-align: center;">Symposium 5 Challenges and perspectives on HTLV diagnostics Chairs: Tatiane Assone, Universidad de São Paulo, Brazil and Heli Harvala, NHS Blood and Transplant, UK</p> <p style="text-align: center;">O30 Regional differences in HTLV-1 Laboratory Diagnostic Practices Philippa Hetzel, National Reference Laboratory (NRL) / St Vincent's Institute of Medical Research, Australia</p> <p style="text-align: center;">O31 Occult HTLV-1 infection: Persistent infection without seroconversion in Japanese macaque infants Maureen Kidiga, Kyoto University, Japan</p> <p style="text-align: center;">O32 Identification of natural remission of mother-to-child retroviral transmission Poonam Grover, Kyoto University, Japan</p> <p style="text-align: center;">O33 A viral clonality evenness score to identify HTLV-1 asymptomatic carriers at high risk of progression to ATL Anne Van den Broeke, Institut Jules Bordet, Brussels & GIGA Institute ULiège, Liège, Belgium</p> <p style="text-align: center;">O34 Multinational Consensus: A International Model of Care for HTLV Follow-Up Clinical Services made accessible to Blood Donors diagnosed with HTLV Fabiola Martin, School of Public Health, The University of Queensland / Canberra Sexual Health Centre, The Canberra Hospital, Australia</p>
12:10 – 13:10	IRVA AGM
13:10 – 14:05	Lunch - Osler Long room
14:05 – 15:15	<p style="text-align: center;">Symposium 6 How to eliminate HTLV-1 as a public health problem? Chairs: Mirna Biglione, INBIRS UBA-CONICET, Argentina & Dan Bradshaw, UKHSA</p> <p style="text-align: center;">O35 Inter-state technical cooperation to advance the public health response to HTLV in Brazil: a case report of a successful initiative Renata Olívia Gadelha Romero, State Public Health Department of Rio Grande do Norte, Brazil</p> <p style="text-align: center;">O36 Exploring breastfeeding knowledge and attitudes in a sample of Peruvian women living with HTLV-1 Eduardo Gotuzzo, Alexander von Humboldt Tropical Medicine Institute - Cayetano Heredia Peruvian University, Peru</p> <p style="text-align: center;">O37 Making the BLV vaccine available worldwide Luc Willems, National Fund for Scientific Research, Belgium</p> <p style="text-align: center;">O38 Prophylactic vaccination inducing neutralizing antibodies can result in sterile protection from HTLV-1 challenge in cynomolgus macaques Hiroshi Ishii, AIDS Research Center, National Institute of Infectious Diseases, Japan</p> <p style="text-align: center;">O38b Developing prevention and functional cure therapeutics for HTLV-1c in a humanised mouse model</p>



HTLV

CONFERENCE

2nd-5th June 2024

Imperial College London & Royal College of Physicians

	<p>Damian Purcell, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, VIC, Australia</p> <p>O39 Situation of the public health response to HTLV-1 in the Region of the Americas Leandro Sereno, Pan American Health Organization, USA</p>
15:15-15:40	<p>Keynote Lecture Protection against Human T cell leukaemia virus type-1 (HTLV1) associated lymphoproliferative disease using attenuated vesicular stomatitis virus (VSV) Glen Barber, University of Miami Miller School of Medicine, USA</p>
15:40 – 16:10	<p>Tea & Coffee - Osler Long room</p>
16:10 – 17:10	<p>Symposium 7 Finding new drug targets for an ancient infection Chairs: Juan-Carlos Ramos, University of Miami, USA & Yorifumi Sato, Kumamoto University, Japan</p> <p>O40 Multi-cohort cross-omics analysis reveals disease mechanisms and therapeutic targets in HAM/TSP Johan Van Weyenbergh, KU Leuven, Belgium</p> <p>O41 Development of an antibody-drug conjugate (ADC) targeting CADM1 in ATL cells Aki Tanabe, National Institute of Infectious Diseases, Japan</p> <p>O42 Structure of the Human T-cell Leukaemia Virus capsid protein – a new drug target Ruijie Yu, University of New South Wales, Australia</p> <p>O43 Exploring the potential of the HTLV-1 capsid as a drug target David Jacques, University of New South Wales, Australia</p> <p>O44 Characterization of a new ATLL patient-derived xenograft mouse model and applications for drug testing and therapeutic targeting Ambroise Marçais, Necker Institute, INSERM U1151, Paris, France</p>
17:10 – 19:00	<p>Poster Session – 2 EVEN-numbered posters to be presented (all posters can be displayed) Osler Long room Evening reception with bowl food</p>

DAY 3: Wednesday 5th June 2024 – Royal College of Physicians

09:00 – 10:40	<p>Symposium 8 Neuro-Inflammation Chairs: Yoshihia Yamano, St. Marianna University School of Medicine, Japan & Marzia Puccioni-Soler, Unirio/ufRJ</p> <p>O45 Evaluation of the effectiveness of dolutegravir on neurological outcomes in HTLV-1 patients: an open-label, randomized, controlled pilot study</p>
---------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



HTLV

CONFERENCE

2nd-5th June 2024

Imperial College London & Royal College of Physicians

	<p>Iris Montañaño-Castellón, Federal University of Bahia, Postgraduate Program in Medicine and Health, Brazil</p> <p>O46 Molecular-targeted agents for treatment of HAM/TSP Daisuke Kodama, Joint Research Center for Human Retrovirus Infection, Kagoshima University Campus, Division of Neuroimmunology, Japan</p> <p>O47 The effect of Teriflunomide on clinical signs, inflammatory and viral factors in patients with HAM Zohreh Vahidi, Mashhad University of Medical Sciences, Mashhad, Iran</p> <p>O48 Chronic inflammation and T-cell exhaustion ubiquitous in Central Australian HTLV-1c infection is associated with defective proviruses retaining antisense hbz gene Ashley Hirons, Doherty Institute, The University of Melbourne, Australia</p> <p>O49 Maladaptation to APOBEC3G is linked to HTLV-1 pathogenicity Takafumi Shichijo, Department of Hematology, Kumamoto University, Japan</p> <p>O50 HTLV-1-specific CD4+ T cells contribute to neuroinflammation in HTLV-1-associated myelopathy Margarita Dominguez-Villar, Imperial College London, United Kingdom</p> <p>O51 Lung Injury in macaques linked to HTLV-1C rex-orf-I encoded p16 inhibition of monocytes efferocytosis Sarkis Sarkis, Postdoctoral Fellow, NIH/NCI, USA</p> <p>O52 Integrated multi-omics analyses to explore a novel inflammatory-inducing factor in HAM/TSP Makoto Nakashima, St. Marianna University Graduate School of Medicine, Japan</p>
10:40 – 11:10	<p>Tea & Coffee - Osler Long room</p>
11:10 – 13:00	<p>Symposium 9 Persistence Chairs: Charles Bangham, Imperial College London, UK & Masao Matsuoka, Kumamoto University, Japan</p> <p>O53 Bovine Leukemia Virus antisense transcription is essential for viral replication and oncogenesis Thomas Joris, University of Liège, Belgium</p> <p>O55 Characterising HTLV-1 Elite controllers Morrell Sotomi, Imperial College London, United Kingdom</p> <p>O56 Role of CTCF binding site in HTLV-1 pathogenies in vivo Lee Ratner, Washington University School of Medicine, USA</p> <p>O57 Disabling the oncogenic retrovirus HTLV-1 through CRISPR/Cas9 genome editing Amanda Panfil, The Ohio State University, USA</p> <p>O58 Intragenic silencer of HTLV-1 plays a key role in retroviral latency by recruiting cellular transcription factors, RUNX1, GATA3 and ETS1 Akhinur Rahman, Kumamoto University, Japan</p>



HTLV

CONFERENCE

2nd-5th June 2024

Imperial College London & Royal College of Physicians

	<p>O59 Primary cells from patients with adult T cell leukemia/lymphoma of different ethnicities depend on HTLV-1 Tax expression for NF-κB activation and survival Ali Bazarbachi, American University of Beirut, Lebanon</p> <p>O60 HTLV-1 hijacks a neuronal protein (SNAP25) to address the viral envelope to the viral biofilm and ensure its infectivity Lucas Sareoua, INSERM – CIRI – ENS de Lyon, France</p> <p>O61 Get together and go: New insights into HTLV-1 particle assembly and infectious spread Louis Mansky, University of Minnesota – Twin Cities, USA</p>
13:00 – 14:00	Lunch - Osler Long room
14:00 – 16:00	<p>Symposium 10</p> <p>Keynote Lecture</p> <p>Integrase and reverse transcriptase-inhibitors effectively block HTLV-1 transmission in vitro: HTLV-1 Pre-exposure prophylaxis clinical trials are urgently needed Goedele Maertens, Imperial College London, United Kingdom</p> <p>Workshop highlights feedback</p> <p>Awards & Announcement of IRVA new board members</p> <p>Close and Announcement of HTLV2026</p>